ANG Lifesciences India Ltd
Incorporated in 2006, ANG Lifesciences
India Ltd is in the business of pharmaceuticals products & formulations, and packaging and printing.[1]
- Market Cap ₹ 26.5 Cr.
- Current Price ₹ 20.3
- High / Low ₹ 39.7 / 17.6
- Stock P/E
- Book Value ₹ 45.2
- Dividend Yield 0.00 %
- ROCE -4.18 %
- ROE -17.0 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.41 times its book value
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -8.77% over last 3 years.
- Promoters have pledged 44.9% of their holding.
- Company has high debtors of 262 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 154 | 354 | 220 | 145 | 93 | 86 | |
| 140 | 286 | 205 | 135 | 94 | 89 | |
| Operating Profit | 14 | 68 | 15 | 10 | -1 | -3 |
| OPM % | 9% | 19% | 7% | 7% | -2% | -3% |
| 1 | 1 | 10 | -1 | 2 | 1 | |
| Interest | 4 | 9 | 12 | 11 | 9 | 8 |
| Depreciation | 1 | 6 | 9 | 8 | 7 | 6 |
| Profit before tax | 10 | 54 | 3 | -11 | -16 | -16 |
| Tax % | 31% | 25% | 110% | -5% | -21% | |
| 7 | 40 | -0 | -10 | -12 | -12 | |
| EPS in Rs | 5.26 | 31.02 | -0.20 | -7.77 | -9.50 | -9.02 |
| Dividend Payout % | 0% | 3% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -36% |
| TTM: | -24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -12% |
| 3 Years: | -38% |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -9% |
| Last Year: | -17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 10 | 13 | 13 | 13 | 13 |
| Reserves | 73 | 73 | 63 | 51 | 46 |
| 77 | 71 | 73 | 83 | 90 | |
| 130 | 119 | 92 | 82 | 94 | |
| Total Liabilities | 290 | 276 | 241 | 230 | 243 |
| 93 | 88 | 58 | 57 | 54 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 198 | 188 | 183 | 172 | 189 | |
| Total Assets | 290 | 276 | 241 | 230 | 243 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 25 | 26 | -9 | -0 | ||
| -44 | -9 | 20 | -2 | ||
| 20 | -17 | -10 | 2 | ||
| Net Cash Flow | 0 | -0 | -0 | -0 | |
| Free Cash Flow | -17 | 16 | 9 | -4 | |
| CFO/OP | 37% | 202% | 39% | -272% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 105 | 138 | 184 | 262 | |
| Inventory Days | 59 | 118 | 183 | 331 | |
| Days Payable | 113 | 165 | 254 | 405 | |
| Cash Conversion Cycle | 51 | 91 | 113 | 189 | |
| Working Capital Days | 20 | 24 | 58 | 55 | |
| ROCE % | 9% | 1% | -4% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capacity Utilization - Sterile Dry Powder Injection % ・Standalone data |
|
||||||||||
| Total Employee Strength Number ・Standalone data |
|||||||||||
| Installed Capacity - Tablets (Unit 4 & 5) Million Pieces per Annum ・Standalone data |
|||||||||||
| Trade Receivables Turnover Ratio Times ・Includes some standalone data |
|||||||||||
| Capacity Utilization - Tablets (Unit 4 & 5) % ・Standalone data |
|||||||||||
| Utilized Capacity - Sterile Dry Powder Injection Million Pieces per Annum ・Standalone data |
|||||||||||
| Utilized Capacity - Tablets (Unit 4 & 5) Million Pieces per Annum ・Standalone data |
|||||||||||
| Installed Capacity - Soft Gelatin Capsules (Unit 6) Million Pieces per Annum ・Standalone data |
|||||||||||
| Installed Capacity - Sterile Dry Powder Injection Vials Million Pieces per Annum ・Standalone data |
|||||||||||
| Total Product Portfolio base Number ・Standalone data |
|||||||||||
| Utilized Capacity - Sterile Dry Powder Injection Lakh Pcs ・Standalone data |
|||||||||||
| Capacity Utilization - Soft Gelatin Capsules (Unit 6) % ・Standalone data |
|||||||||||
| Utilized Capacity - Soft Gelatin Capsules (Unit 6) Million Pieces per Annum ・Standalone data |
|||||||||||
| Installed Capacity - Sterile Dry Powder Injection Vials Lakh Pcs ・Standalone data |
|||||||||||
Documents
Announcements
- Closure of Trading Window 25 Mar
-
Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended 31-12-2025
14 Feb - Board approved Q3 & 9M FY26 unaudited results (14-Feb-2026); standalone Q3 loss ₹497.70 lakh., consolidated loss reported too, auditor review unmodified.)","checklist":["Read and extract key facts …
-
Board Meeting Outcome for Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended 31-12-2025
14 Feb - Approved unaudited Q3 and nine-month FY26 results; standalone Q3 loss ₹497.70 lakh; limited review unmodified.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
6 Feb - Revised secretarial compliance report for FY2024-25; delayed share capital audit reconciliation for June and Sept 2024.
-
Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended And Nine Months Ended On 31St December, 2025.
5 Feb - Board meeting 14-Feb-2026 to approve Q3/9M FY2026 unaudited results (ended 31-Dec-2025); trading window closed.
Business Overview:[1][2][3]
ANGLIL is a part of the ANG Group which is a WHO-GMP–certified consortium of pharmaceutical companies. The company is engaged in the manufacturing of pharmaceuticals & allied products which include finished formulations in Non-Beta Lactam, Beta Lactam, Cephalosporin, and Carbapenem segments.